Free tool
Month-by-Month Expectations
Average first-year weight loss, from the pivotal trials.
STEP trials
Cumulative total body-weight loss
15.2%
average at month 12
Month 1
−2%
Appetite change begins, initial dose settling.
Month 3
−7%
Gating checkpoint — dose advance reviewed.
Month 6
−12%
Steady loss, dose near target.
Month 12
−15.2%
Approaching plateau, maintenance-focused.
These curves are population averages from published clinical trials (STEP for semaglutide, SURMOUNT for tirzepatide), not predictions for any individual. Your own trajectory depends on dose tolerance, protein intake, activity, sleep and underlying conditions. Educational only — not a prescription.
Next step
Set realistic targets with a doctor who tracks these curves daily.
A specialist reads your history and labs before anything is prescribed.
We'd rather you check than guess.
refunded if you're not eligible · no obligation